Insulin Enhances Migration and Invasion in Prostate Cancer Cells by Up-Regulation of FOXC2
Open Access
- 17 July 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 10, 481
Abstract
Androgen deprivation therapy (ADT) is the standard treatment for advanced prostate cancer (PCa), yet many patients relapse with lethal metastatic disease. With this loss of androgens, increased cell plasticity has been observed as an adaptive response to ADT. This includes gain of invasive and migratory capabilities, which may contribute to PCa metastasis. Hyperinsulinemia, which develops as a side-effect of ADT, has been associated with increased tumor aggressiveness and faster treatment failure. We investigated the direct effects of insulin in PCa cells that may contribute to this progression. We measured cell migration and invasion induced by insulin using wound healing and transwell assays in a range of PCa cell lines of variable androgen dependency (LNCaP, 22RV1, DuCaP, and DU145 cell lines). To determine the molecular events driving insulin-induced invasion we used transcriptomics, quantitative real time-PCR, and immunoblotting in three PCa cell lines. Insulin increased invasiveness of PCa cells, upregulating Forkhead Box Protein C2 (FOXC2), and activating key PCa cell plasticity mechanisms including gene changes consistent with epithelial-to-mesenchymal transition (EMT) and a neuroendocrine phenotype. Additionally, analysis of publicly available clinical PCa tumor data showed metastatic prostate tumors demonstrate a positive correlation between insulin receptor expression and the EMT transcription factor FOXC2. The insulin receptor is not suitable to target clinically however, our data shows that actions of insulin in PCa cells may be suppressed by inhibiting downstream signaling molecules, PI3K and ERK1/2. This study identifies for the first time, a mechanism for insulin-driven cancer cell motility and supports the concept that targeting insulin signaling at the level of the PCa tumor may extend the therapeutic efficacy of ADT.Keywords
Funding Information
- Movember Foundation
- Prostate Cancer Foundation of Australia
- Cure Cancer Australia Foundation
- Cancer Council Queensland
- Department of Health, Disability and Ageing
This publication has 72 references indexed in Scilit:
- New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising MedicationInternational Journal of Cell Biology, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate CancerAdvances in Urology, 2012
- Pten Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor CellsCancer Research, 2012
- Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cellsThe Prostate, 2010
- Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysisThe Lancet Oncology, 2008
- Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancerCancer, 2008
- GenePattern 2.0Nature Genetics, 2006
- A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgensBiochemical and Biophysical Research Communications, 1990